4,182 Shares in Health Catalyst, Inc. (NASDAQ:HCAT) Bought by Quest Partners LLC

Quest Partners LLC acquired a new position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) during the 3rd quarter, Holdings Channel.com reports. The firm acquired 4,182 shares of the company’s stock, valued at approximately $34,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Summit Global Investments lifted its position in Health Catalyst by 8.1% in the 3rd quarter. Summit Global Investments now owns 66,544 shares of the company’s stock valued at $542,000 after acquiring an additional 4,991 shares in the last quarter. Impax Asset Management Group plc raised its stake in Health Catalyst by 16.4% in the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after acquiring an additional 360,201 shares during the period. Harbor Capital Advisors Inc. raised its position in shares of Health Catalyst by 21.3% in the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after purchasing an additional 2,064 shares during the period. Janney Montgomery Scott LLC bought a new stake in shares of Health Catalyst during the third quarter worth approximately $897,000. Finally, Nepsis Inc. lifted its holdings in shares of Health Catalyst by 67.9% during the third quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock worth $17,131,000 after buying an additional 851,448 shares in the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Price Performance

HCAT stock opened at $8.83 on Monday. The firm has a market capitalization of $537.29 million, a P/E ratio of -6.54 and a beta of 1.32. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a 50 day moving average of $8.12 and a 200-day moving average of $7.33. Health Catalyst, Inc. has a 12 month low of $5.42 and a 12 month high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. Health Catalyst’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.22) earnings per share. As a group, sell-side analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares in the company, valued at approximately $1,062,018.64. This represents a 5.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares in the company, valued at approximately $1,847,460.82. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,068 shares of company stock valued at $257,555. 2.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Evercore ISI lifted their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th. Piper Sandler reiterated an “overweight” rating and set a $12.00 target price (up from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. JPMorgan Chase & Co. upped their price target on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Finally, Citigroup upped their price target on shares of Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Health Catalyst presently has an average rating of “Moderate Buy” and an average price target of $11.79.

Health Catalyst Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.